ARTICLE | Clinical News

Isis Pharmaceuticals preclinical data

April 7, 2014 7:00 AM UTC

In a mouse model of HBV infection, subcutaneous doses of >=11 mg/kg weekly ISIS-HBVRx dose-dependently reduced serum and liver viral markers of HBV infection. Data will be presented at the European Association for the Study of the Liver meeting in London this month. A Phase I trial evaluating ISIS-HBVRx in about 30 healthy volunteers is slated to complete this year. ISIS-HBVRx is an antisense oligonucleotide targeting HBV RNA. ...